Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).

No abstract is available for this paper.

• Publication year

  1984

• Venue

  The Lancet

• Publication date

  1984-05-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(84)91452-1PMID 6143976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME: A Double-blind Controlled Trial

  1983cited by this paper
• Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

  1983cited by this paper
• Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.

  1982cited by this paper
• Deleterious effects of hydralazine in patients with pulmonary hypertension.

  1982cited by this paper
• Remission of primary pulmonary hypertension during treatment with diazoxide.

  1981cited by this paper
• Oral hydralazine therapy for primary pulmonary hypertension.

  1980cited by this paper
• Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension.

  1980cited by this paper

• Editorial: 10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension from the GRIPHON study and its open-label extension - big data-small impact.

  2026cites this paper
• Cyclic Nucleotide Phosphodiesterase Families as Targets to Treat Pulmonary Arterial Hypertension: Beyond PDE5 Inhibitors?

  2025cites this paper
• Introducing Historical Vignettes in Pulmonary Circulation.

  2025cites this paper
• Important negative trials in pulmonary hypertension.

  2025cites this paper
• Milestones in paediatric cardiology: how prostaglandins revolutionised the management of CHD.

  2025cites this paper
• How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension

  2025cites this paper
• Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension

  2022cites this paper
• Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future.

  2021cites this paper
• Lung transplantation for pulmonary hypertension

  2021cites this paper
• Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group

  2021cites this paper
• Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension

  2021cites this paper
• Treating the Right Ventricle Directly in Pulmonary Hypertension

  2021cites this paper
• Looking PHorward to Improving Long-Term Outcomes in Pulmonary Arterial Hypertension

  2020cites this paper
• Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension

  2020cites this paper
• Pulmonary Hypertension: Controversial and Emerging Topics

  2020cites this paper
• Prävalenz der pulmonalen Hypertonie bei Dialysepatienten mit terminaler Niereninsuffizienz

  2020cites this paper
• Childhood Pulmonary Arterial Hypertension

  2019cites this paper
• Drug repositioning in pulmonary arterial hypertension: challenges and opportunities

  2019cites this paper
• The role of Tumour Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) in Pulmonary Arterial Hypertension

  2018cites this paper
• Inhalation of repurposed drugs to treat pulmonary hypertension☆

  2018cites this paper
• Pulmonary Arterial Hypertension.

  2018cites this paper
• Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience

  2017cites this paper
• Use of Parenteral Prostanoids: Important Insights for CHEST Physicians.

  2016cites this paper
• Prediction of New Diagnostic and Therapeutic Approaches in Pulmonary Arterial Hypertension by Systems Biology Metho

  2016cites this paper
• Surgery, Devices, Transplantation and Other Interventional Options for the Treatment of Advanced Pulmonary Hypertension

  2016cites this paper
• Contemporary Pharmacotherapies Involving Nitric Oxide, Prostacyclin, and Endothelin Receptor Signaling Pathways

  2016cites this paper
• Therapeutic Options for Childhood Pulmonary Hypertension

  2016cites this paper
• Coupling Factor 6 Is Upregulated in Monocrotaline‐induced Pulmonary Arterial Hypertension in Rats

  2016cites this paper
• The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management.

  2016cites this paper
• Global research trends in the medical therapy of pulmonary arterial hypertension 2000-2014.

  2016cites this paper
• Prostanoid therapies in the management of pulmonary arterial hypertension

  2015cites this paper
• Progress in the understanding and management of pulmonary arterial hypertension

  2015cites this paper
• after cessation of prostacyclin infusion in sheep Angiotensin II mediates systemic rebound hypertension

  2015cites this paper
• Prostacyclin Therapy for Pulmonary Arterial Hypertension

  2015cites this paper
• Current treatment approaches to pulmonary arterial hypertension.

  2015cites this paper
• Prostanoid therapies in the management of pulmonary arterial hypertension

  2015cites this paper
• The Shortened Unnatural Life History of Primary Pulmonary Hypertension

  2015cites this paper
• Mechanisms of disease Progress in the understanding and management of pulmonary arterial hypertension

  2015cites this paper
• Medikamentöse Therapie der pulmonalen Hypertonie

  2015cites this paper
• TheEffect ofAnticoagulant Therapy in Primary andAnorectic Drug-Induced Pulmonary Hypertension*

  2015cites this paper
• Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments

  2014cites this paper
• Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries

  2014cites this paper
• Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.

  2014cites this paper
• Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.

  2014cites this paper
• Translational research in pulmonary hypertension: challenge and opportunity

  2014cites this paper
• EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.

  2014cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

  2014cites this paper
• Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group

  2014cites this paper
• Lung transplantation: perioperative pharmacology and anesthetic considerations.

  2014cites this paper
• Interdisciplinary Concepts in Cardiovascular Health

  2014cites this paper
• A practical approach to vascular pathology in pulmonary hypertension

  2013cites this paper
• Gene Transfer Therapy by Either Type 1 or Type 2 Adeno-Associated Virus Expressing Human Prostaglandin I2 Synthase Gene is Effective for Treatment of Pulmonary Arterial Hypertension

  2013cites this paper
• Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.

  2013cites this paper
• Pulmonary arterial hypertension

  2013cites this paper
• Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

  2013cites this paper
• Standard nonspecific therapies in the management of pulmonary arterial hypertension.

  2013cites this paper
• Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes

  2013cites this paper
• Prostacyclins.

  2013cites this paper
• Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.

  2013cites this paper
• Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.

  2013cites this paper
• A novel channelopathy in pulmonary arterial hypertension.

  2013cites this paper
• WHO Group 1 pulmonary arterial hypertension: current and investigative therapies.

  2012cites this paper
• 72 – Childhood Pulmonary Arterial Hypertension

  2012cites this paper
• Pulmonary hypertension-"state of the art" management in 2012.

  2012cites this paper
• A Review of its Pharmacology and Therapeutic Efficacy in the Treatment of Peripheral Arterial Disease and Pulmonary Arterial Hypertension

  2012influential citation
• Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral.

  2012cites this paper
• Lung Transplantation and Role for Novel Extracorporeal Support in Pulmonary Hypertension

  2012cites this paper
• Drug Treatment of Pulmonary Arterial Hypertension

  2012cites this paper
• Current Management of Primary Pulmonary Hypertension

  2012cites this paper
• Pathophysiological role and therapeutic potential of neuregulin-1 in pulmonary arterial hypertension

  2012cites this paper
• Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted

  2012cites this paper
• Pediatric pulmonary arterial hypertension: current and emerging therapeutic options

  2011cites this paper
• Treatment of pulmonary hypertension: bench to bedside.

  2011cites this paper
• The role of apoptosis in a BMPR2 mutant model of pulmonary arterial hypertension

  2011cites this paper
• [Update in the diagnosis and treatment of pulmonary hypertension].

  2011cites this paper
• Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension.

  2011cites this paper
• Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs.

  2011cites this paper
• Current and Emerging Therapies in Pulmonary Arterial Hypertension: Focus on Treprostinil

  2011cites this paper
• Non-invasive evaluation, therapy and transplantation in children with pulmonary arterial hypertension

  2011cites this paper
• Epidural Anesthesia for Cesarean Delivery in a Patient With Severe Pulmonary Artery Hypertension and a Right-to-Left Shunt.

  2011cites this paper
• Advances in the Management of Pediatric Pulmonary Hypertension

  2011cites this paper
• Lung transplantation for pulmonary hypertension

  2011cites this paper
• The Influence of the Major Vasoactive Mediators Relevant to the Pathogenesis of Pulmonary Hypertension

  2011cites this paper
• Clinical and molecular genetic features of hereditary pulmonary arterial hypertension.

  2011cites this paper
• Role of Endothelium in the Development of Pulmonary Hypertension

  2011cites this paper
• Looking to the future: a new decade of pulmonary arterial hypertension therapy

  2011cites this paper
• Alternatives to Lung Transplantation: of Pulmonary Arterial Hypertension

  2011cites this paper
• The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension

  2011cites this paper
• Prostacyclin and Prostaglandins

  2011influential citation
• Role of Thrombospondin-1 in pulmonary hypertension : a proof of concept

  2011cites this paper
• Alternatives to lung transplantation: treatment of pulmonary arterial hypertension.

  2011cites this paper
• How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?

  2010cites this paper
• Genomics of pulmonary arterial hypertension: implications for therapy.

  2010cites this paper
• Endothelial Dysfunction and Inflammation

  2010cites this paper
• Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed.

  2010cites this paper
• Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective.

  2010cites this paper
• Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension.

  2010cites this paper
• [Pulmonary hypertension - historical development, current therapy and perspectives].

  2010cites this paper
• Die pulmonale Hypertonie – historische Entwicklung, derzeitiger Stand der Therapie und Ausblick

  2010cites this paper
• Orally active prostacyclin analogue for cardiovascular disease.

  2010cites this paper